Exploring Cyclooxygenase-2 (COX-2) Inhibitors From Ascidian Derived Ligands For Cancer Treatment: An In-Silico Study.

Authors

  • Mrs. Amudhanila Padmanaban, Dr. Abdul Jaffar Ali Hajamohideen, Mr. Naveen Kumar Mohan, Mrs. Muneeswari Kumar, Mrs. Neelavannan Subashini, Dr. Tamilselvi Madasamy Author

DOI:

https://doi.org/10.48047/CU/54/02/3320-3333

Keywords:

.

Abstract

Cancer remains a significant global health challenge with increasing mortality rates expected in the coming years. Inflammation plays a crucial role in cancer progression, and cyclooxygenase-2 (COX-2) has been identified as a key target for cancer therapy. COX-2 is overexpressed in several cancers and contributes to cancer progression through inflammatory pathways. The therapeutic potential of selective COX-2 inhibitors, such as those derived from non-steroidal anti-inflammatory drugs (NSAIDs), has been widely recognized, although concerns about cardiovascular risks persist. 

Downloads

Download data is not yet available.

References

Taha M, Shah SA, Afifi M, Zulkeflee M, Sultan S, Wadood A, Rahim F, Ismail NH. Morpholine hydrazone scaffold: Synthesis, anticancer activity and docking studies. Chin Chem Lett. 2017;28(3):607-11. doi: 10.1016/j.cclet.2016.10.020.

Liu CJ, Yu SL, Liu YP, Dai XJ, Wu Y, Li RJ, Tao JC. Synthesis, cytotoxic activity evaluation and HQSAR study of novel isosteviol derivatives as potential anticancer agents. Eur J Med Chem. 2016;115:26-40. doi: 10.1016/j.ejmech.2016.03.009.

Downloads

Published

2025-02-10

How to Cite

Exploring Cyclooxygenase-2 (COX-2) Inhibitors From Ascidian Derived Ligands For Cancer Treatment: An In-Silico Study. (Mrs. Amudhanila Padmanaban, Dr. Abdul Jaffar Ali Hajamohideen, Mr. Naveen Kumar Mohan, Mrs. Muneeswari Kumar, Mrs. Neelavannan Subashini, Dr. Tamilselvi Madasamy , Trans.). (2025). Cuestiones De Fisioterapia, 54(2), 3320-3333. https://doi.org/10.48047/CU/54/02/3320-3333